TRIO Pharmaceuticals

TRIO Pharmaceuticals is a cancer immunotherapy company that has pioneered bispecific antibodies for cancer treatment with unprecedented potency and selectivity. TRIO's innovative antibody drugs directly inhibit tumor growth without affecting normal cells, selectively block immune suppression within tumors without targeting current immune checkpoint pathways. TRIO is developing a proprietary dual-action tumor immunotherapy enhancement platform designed to treat cancers with high unmet medical needs by targeting specific antigens on cancer cells and immunosuppressive cells. TRIO has an experienced team that has developed first-class FDA-approved drugs.